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Abstract
The tyrosine kinase receptor epidermal growth factor receptor (EGFR) can be activated by several 
ligands, thus triggering downstream pathways regulating cell growth and survival. Its dysregula tion 
is particularly important for the development and progression of astrocytomas. After the descrip-
tion of its role in glioblastomas (WHO grade IV astrocytomas), an overview on the therapeutic 
strategies target ing EGFR is provided. It analyzes the past and ongoing trials concerning the small 
molecule tyro sine kinase inhibitors, i.e. gefitinib, erlotinib and the combination therapies, the EGFR 
vaccina tion strategies, the antibodies directed against EGFR and finally the intracranially admin-
istered EGFR-targeted therapies. As our understanding of the underlying molecular aberrancies in 
glioblastoma grows, our ability to better target specific subtypes of glioblastoma should improve. 
Molecular biomarker enriched clinical trials may lead to improved patient outcomes.
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Introduction
Epidermal growth factor receptor (EGFR) plays a prominent role in many high-grade astrocytomas. 
Consequently, it is a reasonable and potentially important target in their treatment. This review will 
focus on its role as a therapeutic target in glioblastoma (WHO grade IV astrocytoma). We will elucidate 
the role of EGFR in these tumors and then provide an overview of methods currently used to evaluate 
EGFR status in brain tumor patients. Focus will then shift toward EGFR as a therapeutic target, cover-
ing several different types of therapies and many of their representative clinical trials.
Overview of glioblastoma and the oncogenic role of EGFR
Despite extensive investigation during the last century, glioblastoma remains a disease with an ex-
tremely poor prognosis, and it is nearly invariably fatal within a few years of diagnosis. Glioblastomas 
are grade IV astrocytomas (the highest grade) and are distinguished from their lower grade counter-
parts by the presence of necrosis and neovascularization [1]. A large body of research has shed light 
on a number of molecular pathways that may contribute to the generation, growth, and survival of 
glioblastomas. One of the most important of these dysregulated pathways is the EGFR pathway [2,3]. 
EGFR is a protein encoded on the short arm of chromosome 7. 
A number of ligands activate EGFR, a member of the receptor tyrosine kinase superfamily. These li-
gands include epidermal growth factor (EGF), transforming growth factor-α (TGF-α), heparin-binding 
EGF, amphiregulin, betacellulin, and epiregulin of the EGF protein family [4] as well as members of the 
neuregulin protein family [5]. Inactive EGFR monomers dimerize when bound by ligand, leading to the 
activation of EGFR’s tyrosine kinase activity, resulting in autophosphorylation of tyrosine residues on 
EGFR. Various intracellular proteins and protein complexes can associate with phosphorylated EGFR 
(pEGFR), activating a number of downstream pathways that promote cell growth and division [6].
One of the primary pathways activated by EGFR is the mitogen-activated protein kinase/extracellular 
related signal kinase (MAPK/Erk) pathway, a pathway that eventually leads to activated Ras. Activated 
Figure 1. Ras and MAPK EGFR-mediated growth pathway. 1 – Activating ligand binds to 
extracellular domain of EGFR, and EGFR homodimerizes. 2 – EGFR homodimer autophosphorylates 
at specific tyrosine residues. 3 – GRB2/SOS protein complex associates with phosphorylated 
EGFR. 4 – Ras exchanges GDP for GTP. 5 – Activated Ras-GTP begins kinase cascade that leads to 
enhanced pro-growth gene transcription
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Ras continues a phosphorylation cascade that 
eventually yields activated transcription regula-
tors that promote cell growth and differentia-
tion. Another pathway activated by pEGFR is 
the Akt pathway [6]. Akt promotes cell survival 
through inhibition of Bcl-2-associated death 
promoter (BAD) [7]. Akt also allows for the re-
sumption of the cell cycle when arrested at the 
G1 [8] or G2 [9] stages, and overactive Akt in 
response to abnormally high EGFR activity 
could contribute to oncogenesis. A third down-
stream pathway activated by EGFR is the Jun 
N-terminal kinases (JNK) pathway. When acti-
vated by the EGFR dimer [10], JNK phospho-
rylates c-Jun, a transcription factor important 
in regulation of cell proliferation and apoptosis 
[11]. Through these signal cascades, EGFR has 
the ability to affect the growth, survival, and dif-
ferentiation of many cells in the body, including 
those of glial origin. Two of these pathways are 
depicted (Figure 1 and 2).
Wild-type EGFR (wtEGFR) shows a very high 
prevalence of genetic variants, a phenomenon 
that may be important in glioblastoma. For 
example, a large number of inherited cytosine-
adenine (CA) dinucleotide repeats in intron 1 
of EGFR has been suggested to down-regulate 
transcription of the EGFR gene. In addition, a 
number of single nucleotide polymorphisms (SNPs) have been shown to be potentially associated with 
an increased risk of malignancy [12].
EGFR amplifications and mutations are predominantly found in what has long been described as pri-
mary glioblastoma [13]. Primary (de novo) glioblastoma comprises glioblastoma which arise with-
out evidence of transformation from a lower grade glioma (secondary glioblastoma). However, recent 
work has identified more specific glioblastoma subtypes, each with associated sets of mutations. Four 
molecular subtypes have been described. The “classical” subtype is represented by tumors with paired 
chromosome 7 amplification/chromosome 10 deletion (100% of “classical” tumors), EGFR amplifica-
tion (97%), and EGFR mutation (> 50%) [14]. Additionally, the “classical” subtype lacks some other 
common glioblastoma mutations. Other glioblastoma subtypes include the “mesenchymal”, “proneu-
ral”, and “neural” subtypes, each with their own unique molecular or genetic profiles. Notably, these 
subtypes infrequently exhibit EGFR amplification [14]. Recently, in the prognostically favorable isoci-
trate dehydrogenase 1 (IDH1) mutated (non-mesenchymal subtypes) glioblastomas, areas of focal am-
plification of EGFR have been demonstrated [15].
The EGFR mutation most commonly detected in glioblastoma is EGFRvIII [16], found in 12 of 22 
“classical” glioblastomas in one study [14]. When present, it is nearly always found concurrently with 
EGFR gene amplification and overexpression. The reported incidence of this mutation in glioblastoma 
varies throughout the literature. EGFRvIII involves a deletion of exons 2-7 (amino acids 6-273) in the 
extracellular domain that yields a constitutively active EGFR variant [17] and also creates a unique 
tumor-specific epitope [18]. In addition to upregulation of EGFR activity, there is a growing literature 
Figure 2. PI3K and Akt EGFR-mediated 
anti-apoptotic pathway. 1 – Activating 
ligand binds to extracellular domain of 
EGFR, allowing EGFR to form homodimers 
or heterodimers with other EGFR family 
proteins. 2 – Homodimer/heterodimer 
autophosphorylates at specific tyrosine 
residues. 3 – Phosphorylated homodimer/
heterodimer activates PI3K. 4 – PI3K 
catalyzes PIP3 formation from PIP2. 5 – PIP3 
promotes Akt activation and downstream 
anti-apoptotic pathways
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on potential EGFR downregulators, such as the leucine-rich repeats and immunoglobulin-like domain 
(LRIG) family of proteins, which may also be of therapeutic interest [19].
Finally, both parallel pathways and downstream components of the EGFR pathways are important to 
consider when analyzing the efficacy of EGFR-targeted therapies [20-23].
Other oncogenic pathways in glioblastoma
In addition to EGFR hyperactivity due to EGFR gene mutation or amplification, several other abnor-
mal pathways have been associated with glioblastomas. For example, the p53 tumor suppressor gene is 
mutated or deleted in a significant percentage of glioblastomas. 10-25% of glioblastomas exhibit am-
plification or overexpression of murine double minute 2 (MDM2) [2], a negative regulator of p53 [24]. 
The phosphatase and tensin homologue (PTEN) gene, whose product is an important phosphatase 
involved in kinase activity regulation [25], such as that of EGFR, is abnormal or missing in up to 40% of 
glioblastomas [2]. Finally, recent research has shown that the constitutively active EGFRvIII possesses 
the ability to avoid the ubiquitin proteasome system (UPS) [26]. Phosphorylated wtEGFR is a target 
of Casitas-B linease (Cbl) proteins. This group of proteins polyubiquinate pEGFR, targeting it for in-
ternalization and possibly for lysosomal degradation [27]. However, EGFRvIII does not require phos-
phorylation for its activity, allowing it to circumvent this counterbalancing degradation cascade [26].
Though rare cases of concurrent EGFR overexpression and p53 mutation in glioblastoma have been 
described, these two abnormalities are essentially mutually exclusive. EGFR overexpression is strongly 
associated with primary glioblastoma, with one study reporting an incidence of 73.3%. When such 
amplification was present, it was nearly always coupled with EGFR overexpression [28]. Additionally, 
PTEN and MDM2 mutations are more commonly seen in primary glioblastoma [2]. On the other 
hand, p53 mutations are seen almost solely in secondary glioblastoma. 
Determining EGFR genotype and expression status
Various methods have been pursued to study EGFR gene amplification, EGFR gene mutations, and the 
expression of EGFR at the protein level. All have been applied in glioblastoma.
Fluorescence in situ hybridization (FISH) studies are most commonly used to look for EGFR gene 
amplification in a pattern of double minute chromosomes or as extra copies of the EGFR gene inserted 
in different loci of chromosome 7 [29-31]. Chromogenic in situ hybridization (CISH) has also been 
utilized to look for EGFR gene amplification and correlates with FISH based testing [30,32]. Other 
techniques, including comparative genomic hybridization (CGH) and real time PCR, also have the 
potential for providing information about gene copy number changes like EGFR amplification [31,33].
The presence of EGFR gene mutations, and the EGFRvIII mutation in particular, is established by PCR 
based techniques [31]. The feasibility of performing EGFRvIII mutation analysis on formalin fixed 
paraffin embedded tissue has been documented [34].
Immunohistochemistry (IHC) is widely used to look for the expression of the EGFR protein in tissue 
sections (Figure 3). Strong expression of EGFR detected with an antibody identifying wtEGFR is cor-
related with EGFR gene amplification as assessed by FISH [30,32,35]. IHC with mutation specific anti-
bodies also offers a way to assess the expression of EGFRvIII in glioblastomas [31]. The lack of a com-
mercially available antibody has been a challenge, but new antibodies may become available [36].
Therapeutic modalities targeting EGFR
A number of therapeutic modalities have been employed to target EGFR. Each of these modalities 
carries inherent benefits and limitations, and the potential benefit of each agent depends on its abil-
Figure 3. Microscopic images of blioblastomas illustrating absent (A), weak (B) and strong 
(C) immunoreactivity for wild type EGFR. Cases of strong staining often show membranous 
accentuation of staining as seen in image C. The interpretation of these immunohistochemical 
studies can be complicated by various factors including the entrapment of normal tissue elements 
and intra-tumoral heterogeneity of staining
Author [reference] Drug(s) investigated Phase Patients (n.) Histology Type of disease
Mellinghoff, et al [31] Erlotinib, gefitinib - 82 GBM, AO Recurrent
Lassman, et al [37] Erlotinib, gefitinib I/II 33 GBM, AA, AMG Recurrent or 
progressive
Franceschi, et al [38] Gefitinib II 28 GBM, AA, AO Recurrent
Uhm, et al [39] Gefitinib II 98 GBM Newly diagnosed
Rich, et al [40] Gefitinib II 57 GBM First recurrence
Hegi, et al [41] Gefitinib II 22 GBM Recurrent
van den Bent, et al [42] Erlotinib vs. TMZ or 
carmustine
II 110 GBM Recurrent
Yung, et al [43] Erlotinib II 48 GBM First-relapse
Raizer, et al [44] Erlotinib II 104 GBM, AG Recurrent or  
non-progressive
Sathornsumetee, et al [45] Erlotinib plus bevacizumab II 57 GBM, AG Recurrent
Prados, et al [46] Erlotinib plus TMZ and RT II 65 GBM, GS Newly diagnosed
Brown, et al [47] Erlotinib plus TMZ and RT I/II 97 GBM Newly diagnosed
Peereboom, et al [48] Erlotinib plus TMZ and RT II 27 GBM Newly diagnosed
Reardon, et al [49] Erlotinib plus sirolimus II 32 GBM Recurrent
Kreisl, et al [50] Gefitinibplus everolimus I/II 22 GBM Recurrent
Table I. Summary of small molecule tyrosine kinase inhibitor trials in the treatment of malignant glioma
AA = anaplastic astrocytoma; AG = Anaplastic glioba; AMG = anaplastic mixed glioma; AO = anaplastic 
oligodendroglioma; GBM = glioblastoma; GS = gliosarcoma; RT = radiotherapy; TMZ = temozolomide
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Determining EGFR genotype and expression status
Various methods have been pursued to study EGFR gene amplification, EGFR gene mutations, and the 
expression of EGFR at the protein level. All have been applied in glioblastoma.
Fluorescence in situ hybridization (FISH) studies are most commonly used to look for EGFR gene 
amplification in a pattern of double minute chromosomes or as extra copies of the EGFR gene inserted 
in different loci of chromosome 7 [29-31]. Chromogenic in situ hybridization (CISH) has also been 
utilized to look for EGFR gene amplification and correlates with FISH based testing [30,32]. Other 
techniques, including comparative genomic hybridization (CGH) and real time PCR, also have the 
potential for providing information about gene copy number changes like EGFR amplification [31,33].
The presence of EGFR gene mutations, and the EGFRvIII mutation in particular, is established by PCR 
based techniques [31]. The feasibility of performing EGFRvIII mutation analysis on formalin fixed 
paraffin embedded tissue has been documented [34].
Immunohistochemistry (IHC) is widely used to look for the expression of the EGFR protein in tissue 
sections (Figure 3). Strong expression of EGFR detected with an antibody identifying wtEGFR is cor-
related with EGFR gene amplification as assessed by FISH [30,32,35]. IHC with mutation specific anti-
bodies also offers a way to assess the expression of EGFRvIII in glioblastomas [31]. The lack of a com-
mercially available antibody has been a challenge, but new antibodies may become available [36].
Therapeutic modalities targeting EGFR
A number of therapeutic modalities have been employed to target EGFR. Each of these modalities 
carries inherent benefits and limitations, and the potential benefit of each agent depends on its abil-
Figure 3. Microscopic images of blioblastomas illustrating absent (A), weak (B) and strong 
(C) immunoreactivity for wild type EGFR. Cases of strong staining often show membranous 
accentuation of staining as seen in image C. The interpretation of these immunohistochemical 
studies can be complicated by various factors including the entrapment of normal tissue elements 
and intra-tumoral heterogeneity of staining
Author [reference] Drug(s) investigated Phase Patients (n.) Histology Type of disease
Mellinghoff, et al [31] Erlotinib, gefitinib - 82 GBM, AO Recurrent
Lassman, et al [37] Erlotinib, gefitinib I/II 33 GBM, AA, AMG Recurrent or 
progressive
Franceschi, et al [38] Gefitinib II 28 GBM, AA, AO Recurrent
Uhm, et al [39] Gefitinib II 98 GBM Newly diagnosed
Rich, et al [40] Gefitinib II 57 GBM First recurrence
Hegi, et al [41] Gefitinib II 22 GBM Recurrent
van den Bent, et al [42] Erlotinib vs. TMZ or 
carmustine
II 110 GBM Recurrent
Yung, et al [43] Erlotinib II 48 GBM First-relapse
Raizer, et al [44] Erlotinib II 104 GBM, AG Recurrent or  
non-progressive
Sathornsumetee, et al [45] Erlotinib plus bevacizumab II 57 GBM, AG Recurrent
Prados, et al [46] Erlotinib plus TMZ and RT II 65 GBM, GS Newly diagnosed
Brown, et al [47] Erlotinib plus TMZ and RT I/II 97 GBM Newly diagnosed
Peereboom, et al [48] Erlotinib plus TMZ and RT II 27 GBM Newly diagnosed
Reardon, et al [49] Erlotinib plus sirolimus II 32 GBM Recurrent
Kreisl, et al [50] Gefitinibplus everolimus I/II 22 GBM Recurrent
Table I. Summary of small molecule tyrosine kinase inhibitor trials in the treatment of malignant glioma
AA = anaplastic astrocytoma; AG = Anaplastic glioba; AMG = anaplastic mixed glioma; AO = anaplastic 
oligodendroglioma; GBM = glioblastoma; GS = gliosarcoma; RT = radiotherapy; TMZ = temozolomide
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ity to exert either a direct or indirect effect on the CNS side of the blood brain barrier (BBB). We will 
begin by discussing EGFR-specific small molecule TKIs. These generally well-tolerated orally admin-
istered agents directly target the intracellular component of the EGFR protein. Unfortunately, data on 
intra-CNS and, more importantly, intra-tumoral concentrations of these agents in humans are lim-
ited. In contrast, EGFR vaccines have an indirect effect on the CNS-side of the BBB, since vaccines 
function by stimulating systemic immune response with subsequent trafficking of activated immune 
cells across the BBB. Finally, EGFR-specific antibodies, despite their large size, must be able to cross 
the BBB to have an effect. This process may be facilitated by the presumed relative breakdown of the 
BBB in tumors, as evidenced by the robust enhancement typically noted on post-contrast imaging of 
glioblastoma, but the extent of antibody penetration into brain tumors is still uncertain. Direct ways 
to circumvent the BBB will be discussed briefly in our section on intracranial administration of ther-
apies.
Small molecule tyrosine kinase inhibitors
We will focus our discussion of EGFR-specific small molecule TKIs on gefitinib and erlotinib, both of 
which block the intracellular ATP-binding domain of EGFR. Summaries of gefitinib and erlotinib tri-
als, either alone or in tandem with other treatment agents, can be found in Table I.
Gefitinib
Gefitinib was the first drug of its class marketed for the treatment of malignant tumors, originally ap-
proved by the FDA in 2003 for the treatment of non-small cell lung cancer [51]. It has been investigated 
for utility in the treatment of recurrent or progressive malignant gliomas of both pure astrocytic or 
mixed oligo-astrocytic lineage. One study analyzed samples from 21 tumors from the North Ameri-
can Brain Tumor Consortium (NABTC) Trials 01-03 and 00-01. Treatment with gefitinib yielded no 
subject-to-subject consistencies in levels of pEGFR or two of its affector proteins, phosphorylated ex-
tracellular signal-related kinase (pERK) and pAkt [37]. However, the sole tumor found to be “sensitive” 
to gefitinib, defined as radiographic response per MacDonald criteria [52], did show decreased post-
treatment pAkt levels, while another tumor found to be “insensitive” showed an increase in levels. The 
importance of this finding is unclear due to small sample size [37].
A later phase II trial of gefitinib came to similar conclusions of response inconsistencies. In a small 
fraction of patients with malignant gliomas, gefitinib-treated patients exhibited long-standing control 
of disease progression, extending to over 2 years in some. However, an overall 6 month progression-
free survival (PFS6) rate of only 12.5% was found in the glioblastoma subset, and the median time to 
tumor progression (TTP) for the entire study was a mere 8.4 weeks; median overall survival (OS) was 
just 24.6 weeks. Molecular biomarker assays to determine pre-treatment EGFR and pAKT expression 
levels were performed on 21 out of the 28 patients enrolled; no correlation between these markers and 
either TTP or OS was found, highlighting the difficult nature of predicting patient-to-patient disease 
response to this drug. However, the study did find that a response to gefitinib therapy may be achieved 
at doses much lower than originally thought, noting that a daily oral dose of 250 mg produced nearly 
identical response rates to previous studies of daily oral doses of 500 mg while causing significantly less 
adverse events related to treatment, most notably diarrhea [38]. This finding is of importance in light 
of two studies that independently confirmed a positive correlation between the rate of development of 
diarrhea and OS, suggesting that there is a still unclear but specific subset of patients that may better 
respond to gefitinib therapy [39,40]. Despite this, and despite that gefitinib may efficiently dephos-
phorylate pEGFR in some cases [39], the lack of correlation between treatment response and levels 
of pathway proteins in these cases suggests that gliomagenesis is a much more complex process than 
simple overexpression of a single protein [38,41].
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Erlotinib
In addition to being one of the first investigations of the molecular influences of gefitinib, the study in-
vestigating the response of patients enrolled in the NABTC Trials also analyzed the efficacy of erlotinib 
in the treatment of malignant gliomas. Though structurally similar to gefitinib and working through 
an identical mechanism of action [53], significant differences between the two small molecules were 
discovered. While gefitinib seems to preferentially penetrate tumor tissue over remaining in plasma, 
erlotinib does not. Erlotinib or its active metabolite OSI-420 reach concentrations within glioblastoma 
or non-small cell lung cancer tissue of a mere fraction of concurrent plasma concentrations, whereas 
gefitinib was found to have a three-fold preference of tumor tissue over plasma in some cases. It may 
be that higher tumor tissue levels may be required to achieve more consistent response, and no clear 
correlation between tumor penetration and prognosis has yet been identified [37].
A randomized phase II trial was carried out comparing the efficacy of erlotinib to either temozolomide 
(TMZ) or carmustine in the treatment of recurrent glioblastoma. This study also investigated many 
of the previously described biomarkers in an attempt to disclose predictors of better outcome or in-
creased drug response. However, the study closed early, as PFS6 in the control arm was 24% but only 
11.4% in the arm treated with erlotinib. However, only about half of the tumors studied were found to 
have clearly overactive EGFR protein pathways. Tumors not overexpressing EGFR would not likely be 
expected to respond to EGFR inhibitors, leaving open the likely remote possibility that a better erlo-
tinib-treated response may have been observed if patients were selected for EGFR overactivity before 
being administered treatment. The study did conclude that, similar to gefitinib, patients who developed 
erlotinib-related adverse events, in this case skin toxicity, showed improved OS and PFS6 [42]; similar 
findings have also been reported in the treatment of lung cancer [54].
Other studies have reported similar underwhelming results. Yung et al. report an objective response 
(OR) rate of first-relapse glioblastoma to erlotinib of 8.3%. In this study, although EGFR amplification 
status was not used as inclusion criteria, patients were separated into EGFR-amplified and non-am-
plified subsets post-hoc. Somewhat surprising was the result that patients in the non-amplified group 
treated with erlotinib showed a longer median survival time when compared to EGFR-amplified group 
and also that an OR was observed in the non-amplified group [43]. Stable disease (SD) is the most 
commonly reported favorable response to erlotinib, and response rates vary widely in the literature. 
Raizer et al report SD in 13.3% of patients with recurrent glioblastoma, recurrent anaplastic glioma, or 
nonprogressive glioblastoma following radiotherapy. This study did not select for tumor EGFR ampli-
fication status prior to treatment [44]. 
Combination therapies
As stated, many of the TKI clinical trials did not use EGFR gene amplification status as inclusion cri-
teria for subjects. Nevertheless, even in post-hoc analysis of tumors found to have overactive EGFR-
dependent protein pathways, no consistent clinical response was observed. This further strengthens 
the notion that while TKIs may be sufficiently cytostatic in a specific and small subset of tumor types, 
tumor cell growth and differentiation is a multifactorial process. Because of this, TKIs have been inves-
tigated in combination with other therapies, which will be discussed below.
Bevacizumab, a monoclonal human antibody drug that inhibits angiogenesis by inhibiting vascular 
endothelial growth factor (VEGF), was approved for the treatment of glioblastoma in May of 2009 
[55]. A phase II study of bevacizumab in conjunction with erlotinib in the treatment of recurrent glio-
blastoma and anaplastic glioma provided no added benefit when compared to previous bevacizumab 
investigations [45].
The evidence supporting concurrent use of erlotinib with TMZ and radiotherapy (RT) is conflicting. A 
non-randomized phase II trial combining erlotinib and TMZ during and after RT had improved PFS6 
and median OS (19.3 months) in patients with newly diagnosed glioblastoma or gliosarcoma when 
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compared to historical controls (median OS 14.6 months) [46]. The North Central Cancer Treatment 
Group (NCCTG) phase I/II study N0177 reported no additional benefit of erlotinib when added to 
standard of care TMZ plus RT treatment regimens, with a median OS for newly diagnosed glioblas-
toma of 15.3 months [47]. Another phase II trial adding erlotinib to standard of care demonstrated a 
decreased median PFS of 2.8 months, a decreased median OS of 8.6 months, and a large number of ad-
verse events, including severe toxicities such as thrombocytopenia, anemia, lymphopenia, and febrile 
neutropenia. The investigators proposed that erlotinib may be causing cell cycle arrest, limiting the 
effectiveness of the DNA-alkylating TMZ [48]. Also of note in this and the other two analogous stud-
ies, while EGFR gene amplification was analyzed post-hoc, gene status was again not used as inclusion 
criteria for subjects [46-48].
In an effort to investigate the simultaneous inhibition of EGFR and a downstream pro-cell growth 
protein in the Akt pathway, mammalian target of rapamycin (mTOR), the efficacy of erlotinib plus the 
mTOR inhibitor sirolimus was investigated in the treatment of recurrent glioblastoma. Though the 
treatment regimen was well tolerated, the best outcome was SD. In addition, there was no strong asso-
ciation between tumor marker levels and progression-free survival (PFS) time, and patients were again 
not selected for EGFR amplification [49]. A similar study investigating everolimus, another mTOR 
inhibitor, in conjunction with gefitinib also produced disappointing results. Only 1 patient of 22 with 
recurrent glioblastoma showed PFS6 [50].
EGFR vaccination
The idea that the human immune system can be harnessed to target and eradicate neoplastic cells was 
conceived over a century ago by Ehrlich and Bolduan [56,57]. Numerous studies in the ensuing years 
affirmed that vaccination against tumor antigens results in tumor regression [56,58]. Consequently, the 
potential role of immunotherapy in the treatment of glioblastoma has been pursued with great alacrity.
Central nervous system (CNS) immunoprivilege, due to the presence of the BBB as well as absence of 
draining lymph nodes and resident antigen-presenting cells (APCs) in the brain, was thought to pose 
a distinct challenge to the development of CNS tumor immunotherapies [56,59,60]. In 1948, Medawar 
showed that allogeneic tissue grafts transplanted into the brains of experimental animals were not 
rejected [56,61]. However, more recent evidence demonstrates that immune cells penetrate the BBB 
under normal physiological conditions, antigens egress via cerebrospinal fluid (CSF) and cervical lym-
phatic pathways, and specialized microglia function as surrogate APCs in the CNS by mediating hu-
man leukocyte antigen (HLA) presentation [56,62-67]. Furthermore, in neuro-inflammatory disease 
states, including malignancy, the BBB undergoes changes that hamper its ability to block the trafficking 
of leukocytes and serum proteins into the CNS [56,68]. Thus, peripherally administered therapeutic 
antibodies and tumor-specific antigens under these circumstances are observed to access the CNS with 
physiologically relevant outcomes [56,69].
Immunotherapy can be divided into either active or passive approaches [56,70]. Active immunization 
relies on the native immune system to mount a response against antigens directly inoculated into the 
body or presented by autologous APCs. Passive vaccination, on the other hand, is achieved with the 
infusion of antibodies or antigen-specific T lymphocytes. In this section, we review the active immu-
notherapy strategies that target the tumor-specific EGFR mutation EGFRvIII.
PEPvIII-KLH, also known as CDX-110, is an EGFRvIII-targeted peptide vaccine. More specifically, 
PEPvIII is a 13-amino acid peptide with an additional terminal cysteine that spans the EGFRvIII muta-
tion and has been shown, when coupled to keyhole limpet hemocyanin (KLH), to elicit both humoral 
and cellular immune responses [56,71]. In a preclinical experiment using C3H mice previously chal-
lenged with intracerebral tumors, a one-time vaccination with PEPvIII-KLH in complete Freund’s ad-
juvant resulted in increased median survival [72]. Mice that did not respond to this vaccine were found 
41Reviews in Health Care 2012; 3(1)© SEEd All rights reserved
D. M. Siebert, S. F. Shakur, P. Pytel, R. V. LukasEGFR as a therapeutic target in glioblastoma
to have nearly absent EGFRvIII expression, suggesting that antigen escape variants may be associated 
with treatment failure [56,72].
Based on this preclinical data supporting the safety and efficacy of an EGFRvIII-targeted peptic vac-
cine, two phase II clinical trials were performed. The first such clinical study, ACTIVATE, was a mul-
ticenter trial conducted at Duke University and University of Texas, M.D. Anderson Cancer Center 
that enrolled 19 adults with newly diagnosed EGFRvIII-expressing glioblastoma with a gross-total 
radiographic resection and who had no evidence of radiographic progression after standard of care 
RT and concurrent TMZ chemotherapy [56,71]. Vaccinations consisted of intradermal injections of 
PEPvIII-KLH in combination with granulocyte macrophage-colony stimulating factor (GM-CSF). The 
first three vaccines were given biweekly, followed by monthly injections until radiographic evidence 
of tumor progression or death. The median OS of vaccinated patients was significantly better than 
that of patients in the matched historical cohort, 26.0 months versus 15.0 months, respectively (p = 
0.001). IHC analysis of EGFRvIII expression among recurrent tumors revealed that 82% lost EGFRvIII 
expression. Interestingly, vaccinated patients with an unmethylated MGMT promoter, which confers 
resistance to TMZ, had a longer OS than patients with methylated MGMT (p = 0.062), raising the pos-
sibility that EGFRvIII-targeted vaccines may be an effective alternative for patients with unmethylated 
MGMT [71,73].
The second phase II clinical trial, ACT II, was undertaken by the Duke University group and enrolled 
21 patients [56,74]. Participants received the PEPvIII-KLH vaccine following the same treatment pro-
tocol used in ACTIVATE, except with the addition of concomitant TMZ. Despite TMZ-induced lym-
phopenia, all immune responses were sustained or enhanced with successive TMZ treatments. These 
results were recently confirmed by the multicenter, phase II trial ACT III, which also assessed the im-
munogenicity and potential efficacy of the PEPvIII-KLH vaccine in the context of standard-dose and 
dose-intensified TMZ regimens [75].
A dendritic cell (DC)-based vaccine that targets the EGFRvIII antigen has also been studied. In pre-
clinical experiments, intraperitoneal vaccination with DCs mixed with PEPvIII-KLH and resuspended 
in saline increased median survival by more than 500% (> 300 days, p < 0.001) in C3H mice challenged 
with intracerebral tumors [76]. All vaccinated mice also survived rechallenge with tumor, indicating 
the development of immunological memory.
The first clinical study to evaluate an EGFRvIII-targeted vaccine, which was a DC-based vaccine, was 
the phase I trial, VICTORI, conducted at Duke University [56,77]. This clinical trial enrolled 15 adults 
with newly diagnosed glioblastoma who had undergone a radiographic gross-total resection as well as 
standard RT and had no evidence of radiographic progression. EGFRvIII expression was not an eli-
gibility criterion. Patients underwent leukophoresis to obtain peripheral blood mononuclear cells for 
DC generation. Prior to vaccination, DCs were pulsed with PEPvIII peptide. Patients received three 
vaccines in equal doses, two weeks apart, and were followed without additional therapy until radio-
graphic or clinical progression. The median OS was 18.7 months after vaccination (CI95% 14.5, 25.6) 
and 22.8 months after histological diagnosis (CI95% 17.5, 29). Notably, blood drawn from patients after 
inoculation showed ex vivo evidence of antigen-specific cellular and humoral immune responses. This 
study established the EGFRvIII mutation as a safe and immunogenic tumor-specific target for immu-
notherapy. However, given the high cost and variability associated with autologous DC preparation, the 
study authors decided to pursue additional clinical trials without the use of DCs, instead administering 
an EGFRvIII-targeted peptide vaccine as outlined above.
In summary, these preclinical and clinical studies report encouraging PFS and OS data using a vaccine 
that targets the tumor-specific EGFR mutation, EGFRvIII. All of the completed clinical trials to date on 
EGFRvIII-target vaccines are listed in Table II. It is important to recognize that glioblastoma tumors 
exhibit significant antigenic heterogeneity, thereby confounding immunotherapeutic strategies aimed 
to target a single tumor-specific epitope [56]. Greater antitumor effects may be achieved with the de-
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velopment of multiantigenic vaccines. Moreo-
ver, RT and TMZ are themselves potent muta-
gens that may cause either random or system-
atic mutations in EGFRvIII, resulting in its ap-
parent absence and negating the findings of 
clinical trials in which patients received stand-
ard of care RT and TMZ [78]. Active immuno-
therapy approaches for glioblastoma are prom-
ising but remain incomplete.
EGFR antibodies
EGFR-specific antibodies are used in the treat-
ment of cancer. However, there has long been 
concern about the ability of these large mole-
cules to cross the BBB and reach their intended 
targets [79,80]. 
Mab 425, a humanized murine monoclonal an-
tibody, was one of the first anti-EGFR antibodies investigated. In a phase I trial, it was shown to effec-
tively bind brain tumor tissue [81]. However, a separate phase I/II trial demonstrated no radiographic 
response in recurrent anaplastic astrocytomas or glioblastomas. SD was the best-reported outcome, 
seen in 7 of 13 patients, while the remaining 6 displayed PD [82]. A study of Mab 425 bound to 125I con-
cluded that the antibody plus RT had no added benefit when compared to RT alone in the treatment 
of anaplastic astrocytomas and glioblastomas following surgical resection. In addition, the authors ob-
served no clear evidence of tumoral uptake of EGFR [83].
Cetuximab, another humanized murine monoclonal antibody against EGFR, is currently used for the 
treatment of metastatic colon cancer and squamous cell carcinoma of the head and neck. It partially 
blocks the ligand-binding domain of EGFR, prevents dimerization, and internalizes the EGFR recep-
tor, effectively downregulating EGFR expression [84]. Cetuximab for recurrent high-grade glioma 
(HGG) after failure of standard of care has been evaluated in a phase II study. Systemic administration 
of cetuximab was well tolerated but achieved PFS of greater than 9 months in just 5 of 55 patients, while 
the remaining 50 patients had PFS of less than 6 months; median survival was 5.0 months. In this study, 
patients were screened for EGFR gene amplification status by FISH and then separated into amplified 
and non-amplified groups. However, no statistically significant correlation of EGFR amplification sta-
tus and survival time could be identified [85]. Other trials of cetuximab are ongoing [86].
Nimotuzumab (hR3), a humanized antibody directed against the external domain of EGFR, has been 
investigated in adult and pediatric primary brain tumors. In a phase I/II trial, patients with either grade 
III or IV astrocytomas were treated with nimotuzumab and RT. The group reported relative drug safety 
as well as a median survival time of about 22 months [87].
Intracranial therapies
It has been hypothesized that direct intracranial administration of anti-EGFR therapies could allow 
the local delivery of a more potent drug dose. In a phase I study, nimotuzumab was delivered to post-
surgical resection cavities of either recurrent anaplastic astrocytomas or glioblastomas via intracavitary 
administration, thereby circumventing the BBB. An average of 85.5% of the antibody remained in the 
tumor cavity 1 hour following injection, and it was reasonably well tolerated by patients. As 5 of 11 
patients achieved at least SD, the authors suggest further investigation of the efficacy of intracavitary 
delivery [88].
Clinical trial Year Study design Treatment protocol
VICTORI 2009 Phase I DCs plus  
PEPvIII-KLH








TMZ vs. TMZ 
alone




TMZ vs. TMZ 
alone
Table II. Completed clinical trials on 
EGFRvIII-targeted vaccines.
DC = dendritic cell; KLH = keyhole limpet 
hemocyanin; TMZ = temozolomide
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In a prior phase I study, TP-38, a Pseudomonas toxin-TGF-α construct engineered to target EGFR 
was administered intracerebrally via convection-enhanced delivery (CED) to patients with recurrent 
glioblastoma, gliosarcoma, anaplastic oligodendroglioma, or metastatic spindle cell tumor. Only 2 of 
15 patients responded to treatment, including one complete response sustained for nearly 4 years [89].
Resistance to EGFR-targeted therapy
A number of mechanisms proposed to confer resistance to EGFR-targeted therapies by glioblastoma 
have been elucidated [90]. First, the previously mentioned physical barrier of the BBB limits drug 
penetration. At the molecular level, the Akt pathway can be activated outside of EGFR-dependent 
processes. For instance, the phosphorylation of phosphatidylinositol 4,5-bisphosphate to active phos-
phatidylinositol 3,4,5-triphosphate by phosphatidylinositol 3-kinase (PI3K) allows for subsequent Akt 
activation. This process can occur by activation of PI3K not only by EGFR but also via proteins such as 
platelet-derived growth factor receptor (PDGFR) [13] and the insulin-like growth factor 1 (IGF1) re-
ceptor [91], which has been investigated as a therapeutic target [92]. Mutations of catalytic subunits of 
PI3K have also been demonstrated in glioblastoma [93]. Due to the pivotal role PI3K plays in a number 
of pathways and its ability to activate Akt without dependence on one specific activator such as EGFR, 
it has been proposed as a central target for glioblastoma therapy [94].
Loss of the PTEN gene product allows for unopposed Akt pathway activation via EGFR or phosphati-
dylinositol 3-kinase (PI3K) [90,95]. This loss has been implicated in gliomagenesis [96] as well as in 
tumor resistance to EGFR inhibitors [13,31,97]. Additionally, c-Met, a receptor tyrosine kinase similar 
to EGFR, activates a number of pro-growth pathways and has been shown to be increased in the setting 
of increased and decreased levels of EGFR [90,98,99]. An end product of the synthesis of cholesterol 
by HMG-CoA reductase, dolichol serves to glycosylate EGFR and enhance its function [90,100]. Other 
end products of cholesterol synthesis are used as substrates by enzymes that post-translationally mod-
ify Ras to increase its function as well [90]. Finally, the tumor suppressor STAT3 can form a nuclear 
complex with EGFRvIII that promotes oncogenic transformation in likely multiple but still unclear 
ways [90,101,102].
Conclusions
EGFR is a receptor that serves to activate numerous pathways important in the development, growth, 
proliferation, and survival of glioblastomas. Extensive efforts have been made in its evaluation as a 
potential therapeutic target for these aggressive tumors. Small molecule TKIs, antibodies, and immune 
targeting have all served as potential means to focus attack on EGFR. However, so far, no studies have 
shown significant benefit in outcome, either radiographically or clinically with prolonged PFS or OS.
It is also important to note some of the limitations in the studies summarized in this review. For in-
stance, most of the studies are limited by small sample size and lack of a randomized control group. 
Nevertheless, it can be concluded that the current data on EGFR-specific therapies in glioblastoma do 
not warrant a change in the standard of care for 
clinical practice. Though no approach has been 
clearly demonstrated yet to be effective in the 
majority of patients, our understanding of the 
role of EGFR in glioblastoma has grown in the 
process. This understanding will continue to 
grow via clinical and preclinical research. 
Questions for further research
Further biomarker enriched clinical studies 
may allow for a better understanding of the 
potential benefit of EGFR-targeted therapies.
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